Education
About Us
Working with TipRanks
Follow Us
Jade Biosciences (JBIO)
NASDAQ:JBIO
JBIO Stock Chart & Stats
$16.00
--
Market closed
$16.00
--
Day’s Range― - ―
52-Week Range$6.57 - $100.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)127.19K
Market Cap
$736.07M
Enterprise Value$472.65M
Total Cash (Recent Filing)$198.91M
Total Debt (Recent Filing)$747.00K
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield14.68%
Share Statistics
EPS (TTM)-0.48
Shares Outstanding46,004,204
10 Day Avg. Volume252,880
30 Day Avg. Volume127,195
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.99
Price to Sales (P/S)0.00
P/FCF Ratio-1.06
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.51K
Enterprise Value/Ebitda-7.54
Forecast
1Y Price Target
$22.33Price Target Upside39.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Development FundingA $135 million private placement materially extends cash runway and funds continued clinical development, lowering near-term financing risk and supporting progression toward key 2026 milestones.
Clinical DifferentiationAnalyst notes JADE101's ultra-high affinity and extended half-life could enable more complete APRIL suppression and a dosing interval more than twice as long as the approved anti-APRIL therapy, supporting potential clinical differentiation in IgA nephropathy.
Pipeline DiversificationDisclosure of JADE201, a BAFF receptor-targeting antibody modeled to resemble ianalumab, provides a complementary program to the IgAN candidate and broadens the company's B-cell therapeutic footprint, reducing single-program concentration risk.
Bears Say
Crowded Late-stage PipelineMultiple Phase 3 B-cell modulator programs from established competitors increase the likelihood that larger peers capture significant market share in IgAN, compressing the commercial opportunity for new entrants.
Existing Approved CompetitorPresence of an already approved anti-APRIL therapy creates an adoption hurdle that could limit market share for JADE101 even if clinical advantages are demonstrated.
Valuation And Clinical-risk SensitivityHeavy late-stage competition raises reliance on clearly differentiated clinical results, which could pressure valuation until definitive superiority versus peers is demonstrated.
Jade Biosciences News
JBIO FAQ
What was Jade Biosciences’s price range in the past 12 months?
Jade Biosciences lowest stock price was $6.57 and its highest was $100.10 in the past 12 months.
What is Jade Biosciences’s market cap?
Jade Biosciences’s market cap is $736.07M.
When is Jade Biosciences’s upcoming earnings report date?
Jade Biosciences’s upcoming earnings report date is May 18, 2026 which is in 102 days.
How were Jade Biosciences’s earnings last quarter?
Jade Biosciences released its earnings results on Nov 13, 2025. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.671 by $0.191.
Is Jade Biosciences overvalued?
According to Wall Street analysts Jade Biosciences’s price is currently Undervalued.
Does Jade Biosciences pay dividends?
Jade Biosciences pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 14.68%. See more information on Jade Biosciences dividends here
What is Jade Biosciences’s EPS estimate?
Jade Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jade Biosciences have?
Jade Biosciences has 46,004,204 shares outstanding.
What happened to Jade Biosciences’s price movement after its last earnings report?
Jade Biosciences reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.671. Following the earnings report the stock price went up 10.537%.
Which hedge fund is a major shareholder of Jade Biosciences?
Currently, no hedge funds are holding shares in JBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jade Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.33 (39.56% Upside)
$22.33 (39.56% Upside)
Hedge Fund Trend
Decreased
By 106.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 6.9%
Last 30 Days ▲ 12.6%
Last 30 Days ▲ 12.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.45%
12-Months-Change
Fundamentals
Return on Equity
-50.23%
Trailing 12-Months
Asset Growth
100.52%
Trailing 12-Months
Company Description
Jade Biosciences
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO Stock 12 Month Forecast
Average Price Target
$22.33
▲(39.56% Upside)
Technical Analysis
Ownership Overview
12.79% Insiders
13.93% Mutual Funds
44.33% Other Institutional Investors
21.31% Public Companies and
Individual Investors